Laboratory Corporation of America Holdings (LabCorp), Morrisville, NC, 27560, USA.
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
J Transl Med. 2017 Oct 27;15(1):219. doi: 10.1186/s12967-017-1321-6.
GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation.
Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits.
GlycA 是一种新型的全身炎症光谱标志物，其个体内变异性低，具有其他有利于在慢性炎症和自身免疫性疾病患者中临床应用的属性。GlycA 的独特之处在于其复合性质，反映了局部和全身炎症期间糖链复杂性和循环急性期蛋白水平的增加。来自横断面、观察性和干预性研究的 GlycA 近期研究提供了丰富的信息，表明 GlycA 在急性和慢性炎症中升高，预测健康个体的死亡，并且与类风湿关节炎、银屑病和狼疮等慢性炎症性疾病患者的疾病严重程度相关。此外，在银屑病的生物治疗后，皮肤疾病严重程度的降低伴随着 GlycA 水平的降低和血管炎症的改善。
综上所述，这些发现表明 GlycA 是一种跟踪全身炎症和亚临床血管炎症的标志物。然而，需要进行更大规模的前瞻性研究和随机试验，以评估新型疗法对慢性炎症患者 GlycA 的影响，这可能伴随着心血管获益。
